• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白塞病患者基质金属蛋白酶-2和-3水平及其与血管动脉瘤或神经受累的关系

Matrix Metalloproteinase-2 and -3 Levels in Patients with Behçet's Disease and Implication for the Presence of Vascular Aneurysm or Neurologic Involvement.

作者信息

Talu Erten Pinar, Keser Gökhan, Durusoy Raika, Kocaer Sinem Burcu, Aksu Kenan

机构信息

Department of Internal Medicine, Medicana International Izmir Hospital, Division of Rheumatology, Izmir, Turkey.

Department of Internal Medicine, Ege University, Division of Rheumatology, Faculty of Medicine, Izmir, Turkey.

出版信息

Eur J Rheumatol. 2023 Jul;10(3):101-106. doi: 10.5152/eurjrheum.2023.23007.

DOI:10.5152/eurjrheum.2023.23007
PMID:37681256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10543994/
Abstract

BACKGROUND

Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as caus- ing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix. Increased levels of metalloproteinase-9 and metal- loproteinase-2 have been previously reported in Behçet's disease.

METHODS

In this cross-sectional study, metalloproteinase-2 and metalloproteinase-3 serum levels were investigated in 103 patients with Behçet's disease and 69 healthy controls, using Invitrogen immunoassay human metalloproteinase-2 and metalloproteinase-3 ELISA kits.

RESULTS

Serum metalloproteinase-2 and metalloproteinase-3 levels were significantly higher in the Behçet's disease group compared to healthy controls. Besides, serum metalloproteinase-3 levels were significantly higher in subgroups of Behçet's disease with aneurysmal vascular involvement and with neurological involvement. However, metalloproteinase-2 and metalloproteinase-3 serum levels did not show a positive correlation with disease activity.

CONCLUSION

Metalloproteinase-2 and -3 may contribute to the complex pathogenesis of Behçet's dis- ease. More importantly, the detection of very high serum levels of metalloproteinase-3 may predict the formation of an aneurysm, or possibly the presence of neurological involvement in Behçet's dis- ease and may lead the clinician to make an earlier diagnosis of these complications in young male patients with high risk.

摘要

背景

白塞病是一种累及动静脉的系统性血管炎,可导致反复的炎症性多器官疾病。血管受累与死亡率和发病率增加相关。基质金属蛋白酶在炎症部位释放,并降解细胞外基质的各种成分。先前已报道白塞病患者中金属蛋白酶-9和金属蛋白酶-2水平升高。

方法

在这项横断面研究中,使用Invitrogen免疫测定人金属蛋白酶-2和金属蛋白酶-3 ELISA试剂盒,对103例白塞病患者和69例健康对照者的血清金属蛋白酶-2和金属蛋白酶-3水平进行了研究。

结果

与健康对照相比,白塞病组血清金属蛋白酶-2和金属蛋白酶-3水平显著更高。此外,在有动脉瘤性血管受累和神经受累的白塞病亚组中,血清金属蛋白酶-3水平显著更高。然而,金属蛋白酶-2和金属蛋白酶-3血清水平与疾病活动度无正相关。

结论

金属蛋白酶-2和-3可能参与白塞病复杂的发病机制。更重要的是,检测到血清金属蛋白酶-3水平极高可能预示白塞病患者动脉瘤的形成或可能存在神经受累情况,并可能促使临床医生对高危年轻男性患者的这些并发症进行早期诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c069/10543994/524a59e79137/ejr-10-3-101_f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c069/10543994/0bb412d18eb9/ejr-10-3-101_f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c069/10543994/524a59e79137/ejr-10-3-101_f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c069/10543994/0bb412d18eb9/ejr-10-3-101_f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c069/10543994/524a59e79137/ejr-10-3-101_f002.jpg

相似文献

1
Matrix Metalloproteinase-2 and -3 Levels in Patients with Behçet's Disease and Implication for the Presence of Vascular Aneurysm or Neurologic Involvement.白塞病患者基质金属蛋白酶-2和-3水平及其与血管动脉瘤或神经受累的关系
Eur J Rheumatol. 2023 Jul;10(3):101-106. doi: 10.5152/eurjrheum.2023.23007.
2
Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation?白塞病患者血清基质金属蛋白酶-2和基质金属蛋白酶-9:其较高水平是否与伴有动脉瘤形成的血管性白塞病相关?
Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S70-5.
3
The determination of matrix metalloproteinase 9 activity and gene expression levels in Behcet's disease patients with aneurysmal complications.白塞病伴发动脉瘤患者的基质金属蛋白酶 9 活性和基因表达水平的测定。
Clin Rheumatol. 2011 Apr;30(4):515-9. doi: 10.1007/s10067-010-1559-3. Epub 2010 Sep 15.
4
Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement.有眼部受累和无眼部受累的白塞病患者可溶性内皮蛋白C受体水平
Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1603-8. doi: 10.1007/s00417-008-0873-9. Epub 2008 Jul 5.
5
Comparative Metabolomic Profiles of Vascular Involvement in Behçet's Disease.白塞病血管受累的比较代谢组学图谱
Eur J Rheumatol. 2023 Oct;10(4):130-135. doi: 10.5152/eurjrheum.2023.23062.
6
Scoping beyond pulmonary artery involvement; pulmonary involvement in Behcet's disease; a retrospective analysis of 28 patients.超越肺动脉受累范围;贝赫切特病的肺部受累;28 例患者的回顾性分析。
Clin Rheumatol. 2023 Mar;42(3):849-853. doi: 10.1007/s10067-022-06423-5. Epub 2022 Nov 3.
7
The Evaluation of the Relationship between sTREM-1, VEGF-B, and VEGF Gene Expression Levels with Disease Activity of Behçet's Patients.sTREM-1、VEGF-B 和 VEGF 基因表达水平与白塞病患者疾病活动度的关系评估。
Dis Markers. 2018 Oct 21;2018:2649392. doi: 10.1155/2018/2649392. eCollection 2018.
8
Behçet's disease and risk of vascular events.白塞病与血管事件风险
Curr Opin Cardiol. 2016 Jul;31(4):451-7. doi: 10.1097/HCO.0000000000000281.
9
Impact of disease activity on health related quality of life in patients with Behçet's disease: A cross-sectional study.白塞病患者疾病活动度对健康相关生活质量的影响:一项横断面研究。
Ann Med Surg (Lond). 2020 Apr 13;54:43-46. doi: 10.1016/j.amsu.2020.03.010. eCollection 2020 Jun.
10
Pulmonary artery thrombosis as the first presentation of Behçet's syndrome: a case report and review of the literature.肺动脉血栓形成作为白塞综合征的首发表现:病例报告及文献复习。
J Med Case Rep. 2021 Jun 22;15(1):322. doi: 10.1186/s13256-021-02931-1.

本文引用的文献

1
Vascular Behçet's syndrome: an update.血管型贝赫切特综合征:最新进展。
Intern Emerg Med. 2019 Aug;14(5):645-652. doi: 10.1007/s11739-018-1991-y. Epub 2018 Nov 29.
2
(18)F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis.(18)氟脱氧葡萄糖正电子发射断层扫描与血清细胞因子及基质金属蛋白酶在大动脉炎疾病活动度评估中的应用
Rev Bras Reumatol Engl Ed. 2016 Jul-Aug;56(4):299-308. doi: 10.1016/j.rbre.2015.08.007. Epub 2015 Sep 9.
3
Superficial thrombophlebitis (superficial venous thrombosis).
浅静脉血栓形成(浅静脉血栓症)。
BMJ. 2015 Jun 22;350:h2039. doi: 10.1136/bmj.h2039.
4
Association of MMP-9 gene polymorphisms with Behçet's disease risk.基质金属蛋白酶-9基因多态性与白塞病风险的关联。
Immunol Lett. 2015 Mar;164(1):18-24. doi: 10.1016/j.imlet.2015.01.005. Epub 2015 Jan 29.
5
Association between seven single nucleotide polymorphisms involved in inflammation and proteolysis and abdominal aortic aneurysm.参与炎症和蛋白水解的七个单核苷酸多态性与腹主动脉瘤之间的关联。
J Vasc Surg. 2015 May;61(5):1120-8.e1. doi: 10.1016/j.jvs.2013.11.099. Epub 2014 Mar 7.
6
Matrix metalloproteinase-2, -9, -12, and tissue inhibitor of metalloproteinase 2 gene polymorphisms and cutaneous expressions in patients with Behçet's disease.白塞病患者基质金属蛋白酶-2、-9、-12及金属蛋白酶组织抑制剂2基因多态性与皮肤表现
Tissue Antigens. 2012 May;79(5):333-9. doi: 10.1111/j.1399-0039.2012.01863.x. Epub 2012 Mar 19.
7
Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients.血小板可溶性 CD40L 和基质金属蛋白酶 9 活性是白塞病患者的促炎介质。
Thromb Haemost. 2012 Jan;107(1):88-98. doi: 10.1160/TH11-08-0556. Epub 2011 Nov 24.
8
Association between matrix metalloproteinase 9 promoter polymorphisms and Behçet's disease.基质金属蛋白酶 9 启动子多态性与白塞病的相关性研究。
Hum Immunol. 2010 Jul;71(7):717-22. doi: 10.1016/j.humimm.2010.03.009. Epub 2010 Apr 28.
9
The genetics of abdominal aortic aneurysms: a comprehensive meta-analysis involving eight candidate genes in over 16,700 patients.腹主动脉瘤的遗传学:一项涉及超过16700名患者的八个候选基因的综合荟萃分析。
Int Surg. 2009 Oct-Dec;94(4):350-8.
10
Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease.神经白塞病患者脑脊液中 MMP-9 和 TIMP-1 水平升高。
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S52-7.